Clinical Characteristics and Treatment Outcomes of Myeloid Sarcoma in Children: The Experience of the Polish Pediatric Leukemia and Lymphoma Study Group

• DOI: 10.3389/fonc.2022.935373
• Publication Date: 2022-07-07T06:23:54Z
• Authors: Magdalena Samborska; Małgorzata Barańska; Jacek Wachowiak; Jolanta Skalska-S...; Sheanda Thambyrajah; Małgorzata Czogała; Walentyna Balwierz; Sylwia Kołtan; Katarzyna Peszyńs...; Mariusz Wysocki; Tomasz Ociepa; Tomasz Urasiński; Grażyna Wróbel; Jadwiga Węcławek-...; Bogna Ukielska; Alicja Chybicka; Anna Kitszel; Maryna Krawczuk-R...; Anna Szmydki-Baran; Iwona Malinowska; Michał Matysiak; Agnieszka Mizia-M...; Renata Tomaszewska; Tomasz Szczepański; Agnieszka Chodała...; Grażyna Karolczyk; Lucyna Maciejka-K...; Ninela Irga-Jaworska; Wanda Badowska; Michał Dopierała; Paweł Kurzawa; Katarzyna Derwich
• Keywords: Cancer Research; treatment; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; acute myeloid leukemia; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; children; Oncology; myeloid sarcoma; prognosis; RC254-282

IntroductionMyeloid sarcoma (MS) is an extramedullary malignant tumor composed of immature myeloid cells. It occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). MS may coincide with disease diagnosis or precede bone marrow involvement by months or even years; it can also represent the extramedullary manifestation of a relapse (1, 2).AimThe aim of this study is to describe clinical characteristics of children diagnosed with MS in Poland as well as to analyze diagnostic methods, treatment, and outcomes including overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS). The study also attempted to identify factors determining treatment outcomes.PatientsThe study group comprised 43 patients (F=18, M=25) aged 0-18 years (median age, 10.0 years; mean age, 8.8 years) diagnosed with MS based on tumor biopsy and immunohistochemistry or identification of underlying bone marrow disease and extramedullary tumor according to imaging findings.MethodsThe clinical data and diagnostic and therapeutic methods used in the study group were analyzed. A statistical analysis of the treatment outcomes was conducted with STATISTICA v. 13 (StatSoft, Inc., Tulsa, OK, USA) and analysis of survival curves was conducted with MedCalc 11.5.1 (MedCalc Software, Ostend, Belgium). Statistical significance was considered at p<0.05.ResultsIn the study group, MS was most frequently accompanied by AML. The most common site of involvement was skin, followed by orbital region. Skin manifestation of MS was more common in the age group <10 years. The most frequent genetic abnormality was the t(8;21)(q22;q22) translocation. The 5-year OS probability (pOS), 5-year RFS probability (pRFS), and 5-year EFS probability (pEFS) were 0.67 ± 0.08, 0.79 ± 0.07, and 0.65 ± 0.08, respectively. In patients with isolated MS and those with concurrent bone marrow involvement by AML/MDS, pOS values were 0.56 ± 0.12 and 0.84 ± 0.09 (p=0.0251), respectively, and pEFS values were 0.56 ± 0.12 and 0.82 ± 0.08 (p=0.0247), respectively. In patients with and without the t(8;21)(q22;q22) translocation, pEFS values were 0.90 ± 0.09 and 0.51 ± 0.14 (p=0.0490), respectively.ConclusionsMS is a disease with a highly variable clinical course. Worse treatment outcomes were observed in patients with isolated MS compared to those with concurrent bone marrow involvement by AML/MDS. Patients with the t(8;21)(q22;q22) translocation were found to have significantly higher pEFS. MS location, age group, chemotherapy regimen, surgery, and/or radiotherapy did not have a significant influence on treatment outcomes. Further exploration of prognostic factors in children with MS is indicated.